MYCOPHENOLATE MOFETIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mycophenolate Mofetil Hydrochloride, and what generic alternatives are available?
Mycophenolate Mofetil Hydrochloride is a drug marketed by Amneal, Bpi Labs, Meitheal, Mylan Labs Ltd, Par Sterile Products, Rising, Steriscience, and Zydus Pharms. and is included in eight NDAs.
The generic ingredient in MYCOPHENOLATE MOFETIL HYDROCHLORIDE is mycophenolate mofetil hydrochloride. There are thirty-eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the mycophenolate mofetil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mycophenolate Mofetil Hydrochloride
A generic version of MYCOPHENOLATE MOFETIL HYDROCHLORIDE was approved as mycophenolate mofetil hydrochloride by PAR STERILE PRODUCTS on October 28th, 2016.
Summary for MYCOPHENOLATE MOFETIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 11 |
Raw Ingredient (Bulk) Api Vendors: | 25 |
Clinical Trials: | 941 |
Patent Applications: | 137 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MYCOPHENOLATE MOFETIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MYCOPHENOLATE MOFETIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospital, Rouen | Phase 4 |
Children's Hospital of Chongqing Medical University | Phase 2 |
Jewish General Hospital | Phase 2 |
Pharmacology for MYCOPHENOLATE MOFETIL HYDROCHLORIDE
Drug Class | Antimetabolite Immunosuppressant |